Apellis Pharmaceuticals (NASDAQ:APLS) Issues Earnings Results, Misses Estimates By $0.14 EPS

Apellis Pharmaceuticals (NASDAQ:APLS) issued its quarterly earnings results on Tuesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14), Briefing.com reports. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The firm had revenue of $196.83 million during the quarter, compared to analysts’ expectations of $200.00 million. During the same quarter in the prior year, the firm earned ($1.17) EPS. The firm’s revenue was up 78.3% compared to the same quarter last year.

Apellis Pharmaceuticals Stock Performance

Shares of Apellis Pharmaceuticals stock traded up $1.07 on Friday, reaching $29.81. 702,540 shares of the stock were exchanged, compared to its average volume of 1,777,297. The company has a current ratio of 5.08, a quick ratio of 4.18 and a debt-to-equity ratio of 1.73. The firm has a market capitalization of $3.63 billion, a PE ratio of -10.49 and a beta of 0.87. Apellis Pharmaceuticals has a 1-year low of $24.34 and a 1-year high of $73.80. The business has a fifty day moving average price of $31.19 and a two-hundred day moving average price of $37.14.

Analyst Ratings Changes

A number of equities analysts recently commented on APLS shares. Jefferies Financial Group reiterated a “buy” rating and set a $80.00 target price on shares of Apellis Pharmaceuticals in a research note on Wednesday, July 31st. Wedbush raised their target price on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Citigroup lowered their price target on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday. Bank of America cut their price objective on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, JPMorgan Chase & Co. dropped their target price on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating on the stock in a research report on Friday, September 13th. Six equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $51.06.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares of the company’s stock, valued at $3,623,000. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.80% of the stock is owned by corporate insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).